Our data suggest that targeting RNF5 and HDAC pathways represents a therapeutic modality for AML and that RNF5 or RBBP4 abundance could serve as a prognostic marker and means to stratify patients for treatment with HDAC inhibitors. Here, RNF5 is linked to acute myeloid leukemia.